Handok (Chairman & CEO Young-Jin Kim) is committed to innovation and its business has grown both through strategic partnerships with other companies as well as through innovative research. Handok was founded in 1954 and has been listed on the Korea Stock Exchange since 1976. The company has never recorded a deficit year since establishment.

Handok grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. Handok ended its joint venture relationship with Sanofi in 2012 and became an independent company again. Handok changed its company name from Handok Pharmaceutical Co., Ltd to Handok Inc. and declared its vision to become “The Health Innovator” and as Korea’s leading global healthcare company. Handok introduces new products to the Korean market through partnerships, internal R&D, and state-of-the-art manufacturing while maintaining a global standards compliance program.

Handok is a total healthcare company. Handok’s businesses mainly focus on prescription drugs along with consumer health care products, medical devices and in vitro diagnostics, food supplements and medical nutrition.

Handok is one of the leading pharmaceutical companies which highly value ethical business practices. It has fully implemented comprehensive codes of conduct. This commitment has been recognized with the Special Ethical Management Award conferred by the Health Industry CEO Summit in 2008 and the Excellence prize for Transparent Management by Korea’s five major economic organizations including KEF, FKI in 2010.